PMID: 9177492Jan 1, 1997Paper

Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance

Journal of Cancer Research and Clinical Oncology
Y P Hu, J Robert

Abstract

We have evaluated the protein kinase C (PKC) activity in two series of cultured cell lines presenting the multidrug-resistance (MDR) phenotype and in the corresponding wild-type cells: the human KB 3.1, KB A1 and KB 8.5 cell lines, and the rat C6, C6 0.5 and C6 1V cell lines. We have observed an increase in PKC activity in the MDR cell lines of the KB cell lineage, proportional to their degree of resistance to doxorubicin. In contrast, the MDR cell lines of the C6 cell lineage presented no change (C6 0.5) or even decrease (C6 1V) in PKC activity; the basal level of PKC activity in C6 cells was, however, 50-fold higher than in KB 3.1 cells. We have tested, in these lines, the effect of four modulators of MDR: verapamil, cyclosporin A, quinine and S-9788, on doxorubicin acytotoxicity and on PKC activity. We observed that cyclosporin A and S-9788, which were the most active on MDR reversal, were able to inhibit PKC activity in the KB resistant lines as well as in all C6 lines, whereas verapamil and quinine had only marginal effects on PKC activity. The distribution of PKC isoenzymes was studied by Western blots. The PKC alpha, gamma and delta isoforms were increased in the KB resistant lines as compared to wild-type cells, which c...Continue Reading

References

Jan 1, 1991·Pharmacology & Therapeutics·S Stabel, P J Parker
Jan 2, 1991·International Journal of Cancer. Journal International Du Cancer·C LanziF Zunino
Dec 31, 1990·Biochemical and Biophysical Research Communications·W SatoT Tsuruo
Nov 30, 1990·Biochemical and Biophysical Research Communications·B SparatoreS Pontremoli
Jan 30, 1990·Biochemical and Biophysical Research Communications·A AquinoR I Glazer
Feb 15, 1988·International Journal of Cancer. Journal International Du Cancer·S Huet, J Robert
Jan 1, 1989·Annual Review of Biochemistry·J A Endicott, V Ling
Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R L FineB A Chabner
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K UedaI Pastan
Oct 29, 1987·Biochemical and Biophysical Research Communications·S T PalayoorW N Hait
Mar 1, 1994·International Journal of Cancer. Journal International Du Cancer·C MullerG Laurent
Aug 19, 1993·International Journal of Cancer. Journal International Du Cancer·B SchottJ Robert
Jan 1, 1993·Annual Review of Biochemistry·M M Gottesman, I Pastan
Sep 1, 1993·Pharmacology & Therapeutics·A Basu
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S HuetJ Robert
Jan 19, 1996·The Journal of Biological Chemistry·U A GermannM M Gottesman

❮ Previous
Next ❯

Citations

Jul 18, 2001·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M BarancíkA Breier
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D Del BufaloG Zupi
Nov 13, 2008·Cytotechnology·M G RumsbyJ R Warr
Jan 25, 2005·Nephron. Experimental Nephrology·Clarissa R NascimentoMarcia A M Capella
May 13, 2014·The International Journal of Biochemistry & Cell Biology·Tsai-Hsien HungKowit Yu Chong
Jun 5, 2014·Nutrition and Cancer·Harshita ChaudharySriram Seshadri
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Phillip KantharidisJohn Zalcberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.